SCHEMBL257282

SCHEMBL257282

CC1(c2cccc(F)c2)CCC1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 3/20 0.50
SLC6A3 Q01959 3/20 0.50
SLC6A2 P23975 2/20 0.50
KDM1A O60341 2/20 0.47
OPRD1 P41143 2/20 0.42
CHRNA1 P02708 1/20 0.42
CHRNB1 P11230 1/20 0.42
CHRNB2 P17787 1/20 0.42
CHRNB4 P30926 1/20 0.42
CHRNA3 P32297 1/20 0.42
CHRNA4 P43681 1/20 0.42
PSEN1 P49768 1/20 0.41
PSEN2 P49810 1/20 0.41
APH1B Q8WW43 1/20 0.41
NCSTN Q92542 1/20 0.41
APH1A Q96BI3 1/20 0.41
PSENEN Q9NZ42 1/20 0.41
HSD11B1 P28845 1/20 0.40
HSD11B2 P80365 1/20 0.40
HTR2A P28223 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12203836 0.96 SLC6A4 (0.54) SLC6A4SLC6A3SLC6A2KDM1AOPRD1
SCHEMBL17033038 0.92 KDM1A (0.50) SLC6A4SLC6A3SLC6A2KDM1AOPRD1
Ammonia Solution, Strong SCHEMBL28903694 0.90 KDM1A (0.48) SLC6A4SLC6A3SLC6A2KDM1AOPRD1
SCHEMBL6926392 0.83 KDM1A (0.43) SLC6A4SLC6A3SLC6A2KDM1AOPRD1
SCHEMBL26503536 0.83 ICMT (0.47) SLC6A4SLC6A3SLC6A2KDM1AOPRD1
SCHEMBL31067218 0.82 MEN1 (0.43) SLC6A4SLC6A3SLC6A2KDM1AOPRD1
SCHEMBL6926747 0.82 OPRD1 (0.66) SLC6A4SLC6A3SLC6A2KDM1AOPRD1
SCHEMBL14337240 0.80 KDM1A (0.53) SLC6A4SLC6A3SLC6A2KDM1AOPRD1
SCHEMBL6925345 0.78 KDM4E (0.47) SLC6A4SLC6A3SLC6A2KDM1AOPRD1
SCHEMBL22306040 0.76 BACE1 (0.47) SLC6A4SLC6A3SLC6A2OPRD1CHRNA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8895552-B2 Cyclic amide derivative SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2014-11-25 US disclosed
US-8895552-B2 Cyclic amide derivative SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2014-11-25 US disclosed
US-20130217692-A1 CYCLIC AMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2013-08-22 US disclosed
US-20130217692-A1 CYCLIC AMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2013-08-22 US disclosed
EP-2612848-A1 CYCLIC AMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2013-07-10 EP disclosed
WO-2012029942-A1 CYCLIC AMIDE DERIVATIVE 大日本住友製薬株式会社 (JP) 2012-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130217692-A1 CYCLIC AMIDE DERIVATIVE HDAC10, H1-10, H1-0 SLC6A4 3454/4885SLC6A3 3602/4885SLC6A2 3120/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.